Subcortical surface morphometry in substance dependence: An ENIGMA addiction working group study by Chye, Y et al.
 
Chye, Y, Mackey, S, Gutman, BA, Ching, CRK, Batalla, A, Blaine, S, Brooks, SJ, 
Caparelli, EC, Cousijn, J, Dagher, A, Foxe, JJ, Goudriaan, AE, Hester, R, 
Hutchison, K, Jahanshad, N, Kaag, AM, Korucuoglu, O, Li, C-SR, London, ED, 
Lorenzetti, V, Luijten, M, Martin-Santos, R, Meda, SA, Momenan, R, Morales, A, 
Orr, C, Paulus, MP, Pearlson, G, Reneman, L, Schmaal, L, Sinha, R, Solowij, N, 
Stein, DJ, Stein, EA, Tang, D, Uhlmann, A, van Holst, R, Veltman, DJ, Verdejo-
Garcia, A, Wiers, RW, Yuecel, M, Thompson, PM, Conrod, P and Garavan, H
 Subcortical surface morphometry in substance dependence: An ENIGMA 
addiction working group study
http://researchonline.ljmu.ac.uk/id/eprint/12242/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Chye, Y, Mackey, S, Gutman, BA, Ching, CRK, Batalla, A, Blaine, S, Brooks, 
SJ, Caparelli, EC, Cousijn, J, Dagher, A, Foxe, JJ, Goudriaan, AE, Hester, R, 
Hutchison, K, Jahanshad, N, Kaag, AM, Korucuoglu, O, Li, C-SR, London, 
ED, Lorenzetti, V, Luijten, M, Martin-Santos, R, Meda, SA, Momenan, R, 
LJMU Research Online
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
 1 
Subcortical surface morphometry in substance dependence: An ENIGMA addiction 
working group study 
 
Yann Chye1, Scott Mackey2, Boris A Gutman3, Christopher R K Ching4, Albert Batalla5,6, 
Sara Blaine7, Samantha Brooks8, Elisabeth Caparelli9, Janna Cousijn10, Alain Dagher11, John 
J Foxe12, Anna E Goudriaan13,14, Robert Hester15, Kent Hutchison16, Neda Jahanshad4, Anne 
M Kaag10, Ozlem Korucuoglu17, Chiang-Shan R Li7, Edythe D London18, Valentina 
Lorenzetti1,19, Maartje Luijten20, Rocio Martin-Santos6, Shashwath Meda21, Reza 
Momenan22, Angelica Morales18, Catherine Orr3, Martin P Paulus23,24, Godfrey Pearlson7, 
Liesbeth Reneman25, Lianne Schmaal26, Rajita Sinha7, Nadia Solowij27,28, Dan J Stein8, Elliot 
A Stein9, Deborah Tang11, Anne Uhlmann8, Ruth van Holst26, Dick J Veltman29, Antonio 
Verdejo-Garcia1, Reinout W Wiers9, Murat Yücel1, Paul M Thompson4, Patricia Conrod30, 
Hugh Garavan2 
 
1. Brain and Mental Health Research Hub / Addiction and Mental Health Program, Monash 
Institute of Cognitive and Clinical Neurosciences, School of Psychological Sciences, 
Monash University, Australia 
2. Departments of Psychiatry and Psychology, University of Vermont, USA 
3. Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA 
4. Imaging Genetics Center, Mark & Mary Stevens Institute for Neuroimaging & 
Informatics, Department of Neurology, Keck School of Medicine, University of 
Southern California, Marina del Rey, CA, USA 
5. Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Centre 
Utrecht, The Netherlands 
6. Department of Psychiatry and Psychology, Hospital Clinic, IDIBAPS, CIBERSAM, 
Institute of Neuroscience, University of Barcelona, Spain 
7. Departments of Psychiatry and Neuroscience, Yale University School of Medicine, CT, 
USA 
8. SA MRC Unit on Risk & Resilience in Mental Disorders, Dept of Psychiatry and 
Neuroscience Institute, University of Cape Town, South Africa 
9. Neuroimaging Research Branch, Intramural Research Program, National Institute of 
Drug Abuse, USA 
10. Department of Developmental Psychology, University of Amsterdam, The Netherlands 
 2 
11. Brain Imaging Center, Montreal Neurological Institute, McGill University, Canada 
12. Department of Neuroscience & The Ernest J. Del Monte Institute for Neuroscience, 
University of Rochester School of Medicine and Dentistry, NY, USA 
13. Amsterdam UMC, Department of Psychiatry, Amsterdam Institute for Addiction 
Research, University of Amsterdam, The Netherlands 
14. Arkin Mental Health Care, Amsterdam, The Netherlands 
15. Melbourne School of Psychological Sciences, University of Melbourne, Australia 
16. Department of Psychology and Neuroscience, University of Colorado Boulder, CO, USA 
17. Department of Psychiatry, Washington University School of Medicine, MO, USA 
18. Jane and Terry Semel Institute of Neuroscience and Human Behavior, David Geffen 
School of Medicine, University of California at Los Angeles, CA, USA 
19. School of Psychology, Faculty of Health Sciences, Australian Catholic University, 
Australia 
20. Behavioural Science Institute, Radboud University, the Netherlands 
21. Hartford Hospital/IOL, Olin Neuropsychiatry Research Center, Hartford, CT, USA 
22. Clinical NeuroImaging Research Core, Division of Intramural Clinical and Biological 
Research, National Institute of Alcohol Abuse and Alcoholism, USA 
23. VA San Diego Healthcare System and Department of Psychiatry, University of 
California San Diego, CA, USA 
24. Laureate Institute for Brain Research, OK, USA 
25. Department of Radiology and Nuclear Medicine, Amsterdam UMC, location AMC, the 
Netherlands 
26. Department of Psychiatry, University of Amsterdam, the Netherlands 
27. School of Psychology and Illawarra Health and Medical Research Institute, University of 
Wollongong, Australia 
28. The Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), 
Australia 
29. Department of Psychiatry, VU University Medical Center, the Netherlands 
30. Department of Psychiatry, Université de Montreal, CHU Ste Justine Hospital, Canada 
 
Corresponding author: Professor Hugh Garavan, Department of Psychiatry, University of 
Vermont, Burlington, VT, 05405, USA 
Tel: 802-656-9618, Email: hugh.garavan@uvm.edu 
 3 
 
Running title: subcortical shape in addiction 
 
Word count 
Abstract: 250 words 
Article body: 4645 words 
 
Number of figures: 5 
Number of tables: 2 
Supplementary information: 1 
 
 4 
ABSTRACT 
While imaging studies have demonstrated volumetric differences in subcortical structures 
associated with dependence on various abused substances, findings to date have not been 
wholly consistent. Moreover, most studies have not compared brain morphology across those 
dependent on different substances of abuse to identify substance-specific and substance-
general dependence effects. By pooling large multi-national datasets from 33 imaging sites, 
this study examined subcortical surface morphology in 1,628 non-dependent controls and 
2,277 individuals with dependence on alcohol, nicotine, cocaine, methamphetamine, and/or 
cannabis. Subcortical structures were defined by FreeSurfer segmentation and converted to a 
mesh surface to extract two vertex-level metrics – the radial distance (RD) of the structure 
surface from a medial curve and the log of the Jacobian determinant (JD) – that respectively 
describe local thickness and surface area dilation/contraction. Mega-analyses were performed 
on measures of RD and JD to test for the main effect of substance dependence, controlling for 
age, sex, intracranial volume, and imaging site. Widespread differences between dependent 
users and non-dependent controls were found across subcortical structures, driven primarily 
by users dependent on alcohol. Alcohol dependence was associated with localized lower RD 
and JD across most structures, with strongest effects in the hippocampus, thalamus, putamen, 
and amygdala. Meanwhile, nicotine use was associated with greater RD and JD relative to 
non-smokers in multiple regions, with strongest effects in the bilateral hippocampus and right 
nucleus accumbens. By demonstrating subcortical morphological differences unique to 
alcohol and nicotine use, rather than dependence across all substances, results suggest 
substance-specific relationships with subcortical brain structures. 
 
Keywords: addiction; structural MRI; substance dependence 
 
Abbreviations: AlcD = alcohol dependence; NicD = nicotine dependence; CocD = cocaine 
dependence; MetD = methamphetamine dependence; CbD = cannabis dependence; RD = 
radial distance; JD = log of the Jacobian determinant; ICV = intracranial volume 
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INTRODUCTION 
Substance dependence is characterized by compulsive substance-seeking, and a loss of 
control over intake, despite negative social, interpersonal, and occupational consequences 1. 
Substance use disorder can be related to any of a number of licit and illicit substances, 
including alcohol, cannabis, opioids, stimulants, and tobacco 1. While not all substance users 
will experience problems related to use, a significant number will become dependent, 
although the proportion differs between substances. Within the US alone, over 1.5 million 
substance users are admitted to treatment facilities every year for problems related to 
substance use 2, reflecting a huge personal cost, and a severe toll on social and economic 
development. Substance dependence accounts for over 37.6 million disability-adjusted life 
years (DALYs; i.e., number of years lost due to disability and premature mortality) globally 
3. Disability (mental health, social and emotional functioning) also increases with dependence 
severity among users 4. Identifying biomarkers associated with dependence across different 
substances (i.e. alcohol, tobacco, cannabis, opioids, stimulants) may greatly help our 
understanding of dependence and its consequences, and improve the identification of 
individuals most vulnerable to dependence-related harm. 
 
Neuroimaging research over the years has attempted to elucidate brain-based biomarkers (i.e. 
structure, function, and neurochemistry) that may indicate aberrant processes in dependence 
on various substances 5. Separately, these studies have demonstrated volumetric differences 
in common subcortical structures, including the hippocampus, amygdala, striatum, and 
thalamus, in opioid, stimulant, alcohol, tobacco, and cannabis use disorders 6–10. Such 
findings are consistent with the proposed role of these striatal and limbic structures in 
supporting processes (e.g., planning and decision making, reward, and memory) crucially 
involved in the etiology of substance use and dependence 11,12. However, studies have yet to 
compare subcortical structure across multiple substances using the same methods, making it 
difficult to infer substance-specific versus substance-general neural alterations characterizing 
dependence. Furthermore, gross volumetric measures commonly employed by structural 
imaging studies may be unable to capture more localized subcortical differences (i.e. focal 
differences on the vertices or triangular mesh that make up the subcortical surface, as 
opposed to a single volumetric value across the entire structure) that can either be 
generalizable across substances of abuse or specific to particular substances. This is relevant 
as structures such as the hippocampus, amygdala, and striatum may be functionally 
segregated across their subregions and/or topology, given differences in gene expression, 
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receptor distributions (e.g. GABAA, dopamine, and cannabinoid receptors, and innervation 
along the structure 13–19. Different regions of these subcortical structures may therefore be 
differentially associated with substance use and dependence. For example, the basolateral and 
central amygdala are differentially recruited over the course of cocaine-seeking in rats 20. The 
former is suggested to be relevant for the development of substance-seeking ‘habit’, while the 
latter is thought to be responsible for its long-term maintenance, reflecting unique but 
complementary roles in the etiology of substance use 20. The dorsal and ventral regions of the 
hippocampus are also differentially implicated in context-induced and cue-induced 
reinstatement of substance use, due to their greater involvement in cognitive and affective 
functions respectively 16,21,22. Different substances of abuse are further thought to have 
differing cellular and molecular pathways to dependence, raising the potential of substance-
specific dependence effect 23. These observations motivated us to consider more fine-grained 
shape differences in subcortical morphology when delineating individual substance 
dependence-related effects on the brain. 
 
This study was conducted by the Addiction working group of the Enhancing NeuroImaging 
Genetics through Meta-Analysis (ENIGMA) Consortium, which leverages already collected 
neuroimaging datasets to overcome limitations of sample size and statistical power in 
identifying biomarkers of substance dependence 24,25. Our previous study examining 
FreeSurfer-segmented subcortical volumes across a combined sample of 23 research sites 
identified substance-specific effects of alcohol dependence in the amygdala, hippocampus, 
nucleus accumbens, and putamen 26. A nonlinear support vector machine was further able to 
classify alcohol dependence and nicotine dependence above chance levels (despite there 
being no significant nicotine dependence effects on individual subcortical volumes), 
suggesting that there may be nonlinear or multivariate patterns of effects across multiple 
brain areas not captured by standard univariate analysis of regional volumes. Building on this 
result, this study sought to characterize substance-general and substance-specific shape 
variation across the subcortical surfaces, which might better identify fine-grained regional 
effects not captured by a single volumetric measure (i.e. as was the limitation of our previous 
paper, Mackey et al., 2018). This study contained pooled neuroimaging data from 33 research 
sites, adopting a surface-based approach used to quantify subcortical shape variability (i) 
between all dependent users and non-dependent controls, (ii) across dependence groups 
(alcohol, nicotine, cocaine, methamphetamine, or cannabis) and non-dependent controls, and 
(iii) across nicotine use status. This will provide insight into whether dependence on different 
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substances of abuse may be associated with unique and localised effects on the brain, 
specifically on subcortical structures. In turn, such brain effects may have the potential to 
serve as useful biomarkers for risk factors or evidence of recovery from substance 
dependence. 
 
MATERIALS AND METHODS 
Case and control data were contributed from 33 scanning sites from the ENIGMA addiction 
working group 25; http://enigmaaddiction.com). This included a total of 1,535 non-dependent 
controls, and 2,270 individuals with a primary substance dependence diagnosis (according to 
DSM-IV criteria) on one of five substances: alcohol (AlcD), nicotine (NicD), cocaine 
(CocD), methamphetamine (MetD), and cannabis (CbD), although ~8% of dependent users 
met criteria for dependence on more than one substance. Cases were excluded if criteria were 
met for any lifetime history of central nervous system disease, or a current axis I diagnosis 
apart from substance dependence, apart from mood and anxiety disorders. Non-dependent 
controls may have used these substances (i.e. mainly alcohol and nicotine), but did not meet 
diagnostic criteria or were not assessed for substance dependence. Individual site information 
and diagnostic instrument is provided in Supplementary Table 1. All subjects provided 
written informed consent, and all procedures were in accordance with the Declaration of 
Helsinki. 
 
MRI Data Processing 
Site-specific scanner and acquisition details for T1-weighted MR images are available in 
Supplementary Table 1. All scans were prepared (either centrally at the University of 
Vermont or at the respective individual sites) using the FreeSurfer image analysis 
environment (http://surfer.nmr.mgh.harvard.edu/) version 5.3.0, to segment 14 subcortical 
regions (i.e., bilateral accumbens, amygdala, caudate, hippocampus, pallidum, putamen, and 
thalamus) from surrounding brain tissue. All FreeSurfer output underwent quality control at 
each site, according to an established protocol (http://enigma.ini.usc.edu/protocols/imaging-
protocols/), which included outlier detection and visual inspection of all data. A second level 
of quality control was also performed on a random selection of participants from each site, 
centrally at the University of Vermont.  
 
Morphometric analysis on the FreeSurfer-segmented subcortical regions was performed at 
the University of Vermont. This entailed converting subcortical boundaries to a mesh surface 
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using the Medial Daemons method 27,28; http://enigma.ini.usc.edu/ ongoing/enigma-shape-
analysis/). This step includes registration of the FreeSurfer-segmented subcortical structures 
to a master template based on brain images from 200 young adults created by the University 
of Southern California’s Imaging Genetics Center team. By matching their shape curvatures 
and medial features to a master template, mesh representations of the subcortical boundaries 
were generated. All resulting mesh reconstructions were visually inspected by Y.C. for 
quality control. Reconstructions that had significant artifacts (e.g. spikes, holes) or were 
grossly inaccurate upon visual inspection (2.19% of generated structures) were excluded. 
Finally, two vertex-level metrics were derived from the mesh surface, to quantify subcortical 
shape. This included (i) the radial distance (RD), which is the distance between each surface 
vertex and a skeleton core created along the long axis of the structure; and (ii) the natural 
logarithm of the Jacobian determinant (JD), which represents the surface dilation ratio 
necessary to map corresponding vertices on the subject-specific surface to the surface of the 
master template. The logarithm is used to obtain a distribution that is closer to Gaussian. RD 
and JD capture surface measures akin to ‘thickness (from a central skeleton)’ and ‘area’ 
respectively, 29, and are only weakly correlated (i.e., correlation coefficient from our sample, 
r = .0228, CI = [.0226, .0230]). They thus complement each other in providing information 
on localized grey matter changes across subcortical structures. The number of vertices per 
structure was consistent across subjects, as defined by the master template (accumbens = 930; 
amygdala = 1368; caudate = 2502; hippocampus = 2502; putamen = 2502; thalamus = 2502; 
pallidum = 1254). See Fig. 1 for an overview of the vertex-wise shape metrics employed. 
 
Statistical Analysis 
Three sets of tests examined substance-general and substance-specific correlates of 
dependence, using an optimized split-half strategy, described in the later paragraph. The first 
set (model I: substance-general model) assessed the main effect of dependence on any 
substance (i.e., dependent users vs. non-dependent control). In these analyses, individuals 
reporting dependence on one or more substance were included.  
 
The second set (model II: substance-specific model) assessed the main effect of individual 
substances of dependence (i.e. AlcD, NicD, CocD, MetD, CbD, versus non-dependent 
controls as a fixed factor with 6 levels). In the second set of analyses, individuals who were 
dependent on more than one substance were excluded, to clarify the association between 
dependence on individual substances and subcortical morphology. However, non-dependent 
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occasional substance use (e.g. recreational alcohol use in either group) was not excluded. 
Effect of AlcD was further validated in a post-hoc analysis with a subsample of 171 AlcD 
participants versus non-dependent controls, to ensure that any observed AlcD effects were 
not due to their comparatively larger sample (n=830) relative to other substance-user groups 
in this study (n=171-565). The subsample of 171 AlcD participants were created by 
systematically selecting one in five AlcD participants, ordered by site, sex, and age, to ensure 
that these covariates were matched across selected and non-selected samples. 
 
The third set of analyses (model III: nicotine-disambiguation model) investigated nicotine use 
effects. The large number of non-dependent controls and individuals diagnosed with 
dependence who use nicotine may have affected the search for nicotine-related results in the 
second model. This is particularly important as individual studies that recruited users on 
AlcD, CocD, MetD, and CbD may not necessarily screen for nicotine use or dependence. 
Consequently, the third set of analyses compared three groups: individuals with NicD, non-
dependent controls who use nicotine, and non-dependent controls who do not use nicotine.  
 
Similar to the method in our previous paper 26, data for the three models were analysed using 
an optimized split-half strategy whereby the data were first split into two halves matched for 
site, age, sex, and intracranial volume. Subsequently, the series of linear models were tested 
on each separate half, on the RD and JD measures of each subcortical structure, controlling 
for participants’ age, sex, intracranial volume (ICV, to account for premorbid head size), and 
imaging site. All outputs were corrected using a regional searchlight false discovery rate 
(FDR) method 30 at q =.05, conservatively treating the 14 subcortical structures (i.e., bilateral 
accumbens, amygdala, caudate, hippocampus, pallidum, putamen, and thalamus) and two 
metrics (RD and JD) in each model as a single family of tests. Lastly, the corresponding 
outputs across the split halves were overlaid to identify common regions of significance (i.e., 
vertices that were significant across both splits, henceforth referred to as ‘overlap’). 
 
RESULTS 
Demographic information for the full sample is presented in Table 1. In general, dependent 
samples included more males, were older, and exhibited greater ICV than non-dependent 
controls. Association between sex, age, and ICV are also presented graphically in 
Supplementary Figures 1 and 2. To control for these factors, sex, age, and ICV were included 
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as covariates in the linear models. The effects of sex, age, and ICV on RD and JD are also 
presented graphically in Supplementary Figure 3. 
 
Model I: Substance-general Model 
Dependent users were compared to non-dependent controls. On average, dependent users 
exhibited lower RD and JD values relative to non-dependent controls in the hippocampus and 
amygdala, diffuse areas of the thalamus, and the right nucleus accumbens (Fig. 2). 
 
Model II: Substance-specific Model 
For this model, individuals with dependence on multiple substances (~8%) were excluded, 
resulting in a reduced sample size of 1,535 non-dependent controls and 2,085 dependent 
users. No significant differences emerged from comparisons of NicD vs. non-dependent 
controls, CocD vs. non-dependent controls, MetD vs. non-dependent controls, or CbD vs. 
non-dependent controls. However, AlcD demonstrated significantly smaller RD and JD 
values, particularly across bilateral hippocampus and putamen, and the right amygdala and 
thalamus (Fig. 3). These regions of significance roughly correspond to regions identified in 
Model I. Post-hoc analysis on a smaller subsample of 171 AlcD participants (i.e. the sample 
size of the smallest substance dependence group in our study) similarly showed significantly 
smaller RD and JD values relative to non-dependent controls, suggesting that the observed 
alcohol-specific effect was not due to the comparatively larger AlcD sample relative to other 
substance-user groups in our study (n=171-565). 
 
Model III: Nicotine-disambiguation Model 
Finally, model III was run to clarify the potential effect of NicD, by minimizing the potential 
confounding influence of cigarette smoking in non-dependent controls. Control participants 
recruited from all sites were separated into 918 non-smoking controls, 189 smoking controls, 
after excluding participants without information on smoking status. These groups, and the 
group of 565 NicD participants that were originally recruited by sites that tested for smoking 
effects, were compared. NicD participants demonstrated significantly higher RD and JD 
values relative to non-smoking controls, indicating greater volume and surface area across 
bilateral regions of the hippocampus, thalamus, putamen, and the right nucleus accumbens 
(Fig. 4). 
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Similarly smoking controls (who were not assessed for nicotine dependence by the recruiting 
sites) demonstrated inflated structures relative to non-smoking controls, across the 
hippocampus, thalamus, diffuse regions of the putamen, and the right nucleus accumbens 
(Fig. 5). There was no significant difference between NicD and smoking controls. 
 
Common regions of significance across both splits (i.e., overlap) are reported in Table 2 as 
the percentage of significant vertices relative to the total number of vertices across each 
structure. 
 
DISCUSSION 
Our previous volumetric mega-analysis of individuals dependent on one of five substances 
(alcohol, nicotine, cocaine, methamphetamine, and cannabis) found lower amygdala, 
hippocampus, nucleus accumbens, and putamen volume in alcohol dependent relative to non-
dependent controls, but no subcortical associations specific to dependence on any of the other 
substances 26. The current follow-up investigation adopts a more sensitive measure that 
allows the quantification of localized differences at the vertex-level to closely examine 
subcortical surface changes that may not have been detectable in our previous study. In a 
larger combined sample of 3,805 individuals, we demonstrated lower RD and JD values 
consistent with lower thickness and surface area in subcortical structures associated with 
substance dependence, mainly along the hippocampus, amygdala, thalamus, and accumbens, 
across substances of abuse. Such differences were driven by alcohol dependence and no 
subcortical differences were observed for cocaine, methamphetamine, or cannabis users in 
relation to non-dependent controls, in agreement with our previous paper 26. Further 
examination of nicotine dependence relative to non-smoking controls, and smoking controls 
relative to non-smoking controls, surprisingly demonstrated an inverse association of higher 
RD and JD values consistent with greater thickness and greater surface area across the 
hippocampus, thalamus, and right accumbens in both nicotine dependence and smoking 
controls relative to non-smoking controls.  
 
The striking alcohol-specific effect on subcortical structures (in particular, the striatal and 
limbic structures) is consistent with our previous ENIGMA study on gray matter volume in 
substance dependence, which demonstrated lower volume in widespread cortical and 
subcortical regions specific to alcohol dependence 26. The absence of a subcortical 
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association with cocaine, methamphetamine, and cannabis is interesting given the literature 
implicating striatal and limbic structures in the development of dependence towards these 
substances 7,31. To ensure that the observed alcohol-specific effect was not due to the 
comparatively larger alcohol dependence sample (n=830) relative to other substances 
(n=171-565) in our study, we re-ran the substance-specific model with a subsample of 171 
alcohol dependence users. Results remained consistent and significant, suggesting that 
alcohol dependence effect was robust, even across a much smaller sample. The individual 
effects of other illicit substances on brain morphology may be subtler than previously 
assumed 6,7,10. Alternatively, various moderating influences such as quantity of substance use 
and timed developmental exposure may be relevant in considering brain morphology as 
alcohol use typically starts earlier than the other illicit drugs (e.g. 50% of those who ever 
used alcohol starts at age 14-21, compared to age 16-28 for cannabis and cocaine 32). 
Unfortunately, comparison of use level across different substances was not possible in the 
present samples, as similar substance use histories were not obtained on all subjects at the 
participating sites. An important goal for future studies will be to examine the impact of age 
of onset and lifetime quantity of use on morphological measures in alcohol dependence.  
 
While nicotine dependence effects were not observed in Model II when segregating users into 
their substance of choice, differences were observed in Model III when comparing nicotine-
dependent users to non-smoking controls. The lack of effect of the former model may be due 
to the confounding influence of smoking status within the non-dependent control sample. 
Control samples collected by sites that seek to examine the effect of other illicit substances 
(e.g. cannabis, cocaine, methamphetamine) often do not account for smoking status in their 
samples or deliberately seek to match groups on cigarette use levels. By segregating non-
smoking and smoking controls, Model III sought to tease apart the influence of occasional 
cigarette smoking relative to dependence. Finding greater RD and JD in nicotine-dependent 
users relative to non-smoking controls in the hippocampus, putamen, and thalamus, was in 
agreement with studies linking greater putamen volume with cigarette smoking 33,34, but in 
contrast to previous evidence of smaller thalamus and hippocampus in chronic cigarette 
smokers relative to non-smokers 35–37. Some studies have also reported no thalamic or 
hippocampal volume difference in smokers relative to non-smokers 34,38, reflecting the 
inconsistency of current evidence on nicotine dependence. By pooling a combined sample of 
1,672 subjects, adopting a more sensitive measure of vertex-level morphology, and requiring 
split-half replication, this study provides evidence for a reinterpretation of cigarette smoking-
 13 
related effects on brain morphology. The smoking-related effect was not only observed 
between nicotine dependence and non-smoking controls, but also between smoking controls 
(who were not diagnosed with a nicotine dependence) and non-smoking controls, suggesting 
structural differences associated with use rather than dependence. The proposed exposure-
related effect (as opposed to dependence-related effect) of cigarette smoking is supported by 
a study demonstrating a dose-dependent relationship between nicotine use and enlarged 
putamen volume 33. Nicotinic receptors, that are particularly densely located along regions 
where effects were observed (i.e. hippocampus, thalamus, basal ganglia) 39, and are 
paradoxically upregulated in response to chronic nicotine exposure 40,41, may underlie the 
observed morphological differences.  
 
It is interesting to note that similar cigarette-smoking related effects (i.e. greater RD and JD 
in the hippocampus, thalamus, and putamen) are not apparent in other substance-dependent 
users in our sample, given the high comorbidity between cigarette smoking and other 
substance use, particularly cannabis 42,43. Subcortical morphometry may be subject to an 
interactive effect between nicotine and other substance use. For example, the typically 
observed subcortical differences in users dependent on methamphetamine, cocaine, or 
cannabis 6,7,10 may have been counteracted by an opposing cigarette-smoking effect. 
Unfortunately, the low number of methamphetamine-, cocaine-, or cannabis-dependent 
subjects who are also non-smokers, and the lack of well-characterized smoking level 
information within these substance-dependent users prevents an interrogation of the 
interactive effect between cigarette smoking and other substance use/dependence in brain 
structural effects. 
 
A key structure emerging from this comprehensive examination of substance-related 
subcortical morphology is the hippocampus, being notably implicated (up to >40% of the 
structure’s surface) across the examined models. The hippocampus is a crucial structure for 
learning and memory - its function is central to substance-related memory processes 
including reinforcement learning and reinstatement of substance use 44. The observed 
hippocampal effect was mostly confined to the hippocampal head and inferior body of the 
left hippocampus, roughly coinciding with the cornu ammonis (CA1) and subicular regions 
45. The CA1 is thought to be important for input integration, and contains a high density of N-
methyl-D-aspartate (NMDA) receptors that are modulated by substance use, in particular 
alcohol 46,47. Alcohol-associated NMDA effects are further thought to contribute to alcohol 
 14 
tolerance and dependence 47. The subiculum receives input from the CA1, and along with the 
CA1, provides the main hippocampal outflow to a range of cortical and subcortical sites 45. 
Both the CA1 and subiculum are particularly affected in neurodegenerative disorders such as 
Alzheimer’s disease 48, reflecting regional vulnerability to age-related atrophy, that may 
further be amplified by chronic alcohol abuse 49. Further, the anterior thalamic sub-region 
was also found in this study to be preferentially affected relative to other sub-regions of the 
thalamus. The anterior thalamus is primarily connected to the hippocampus and frontal 
cortex, with reduced thalamo-frontal projections and anterior thalamic volume being 
particularly associated with increased age and cognitive (attention and memory) decline 50,51. 
The selective vulnerability of the anterior thalamus may further extend to alcohol 
dependence, as demonstrated by this study.  
 
While effects observed in the amygdala were relatively small and diffuse, across both the 
lateral and basal regions 52, they were observed mostly in the right amygdala. This laterality 
effect is in line with previous studies demonstrating a stronger association between the right 
(vs. left) amygdala with substance dependence 53, and risk for developing alcohol dependence 
54. Findings from the latter study also suggest that an amygdala effect may precede 
dependence. The basolateral amygdala, implicated in our study, is also argued to be 
important for reward learning, motivation, and decision making, and therefore relevant in the 
early stages and acquisition of substance dependence (whereas the central amygdala is 
thought to be more involved in stress, negative reinforcement and maintenance of 
dependence) 20,55,56. However, it should be noted that the cross-sectional nature of this study 
prevents us from confirming a causal role of subcortical differences across the trajectory of 
substance dependence. Large scale, longitudinal studies that track the trajectory of brain 
development and substance use, such as the ABCD study (https://abcdstudy.org/) will be 
beneficial in clarifying the direction of association between substance use, dependence, and 
brain morphology. 
 
The current findings should be interpreted in the light of several limitations. First, the 
datasets from multiple sites were collected under differing protocols and scanner sequences. 
The diagnostic instruments adopted by the imaging sites for segregating dependence from 
controls also differ. While these instruments are all validated and reliable, the inter-site 
differences may limit the specificity of study findings. This study attempted to mitigate the 
site issues in scanning and diagnosis by having a single rater visually inspect all subcortical 
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reconstructions and by incorporating site factors in all the statistical models. Conversely, a 
benefit of making inference from multi-site data means that findings might have greater 
generalizability to the wider population, due to the collation of larger samples 57. A second 
concern of adopting a multi-site approach is in the interpretability of findings, particularly in 
relation to the spectrum of dependence severity, lifetime use quantity, or other clinical 
variables of interest such as those that index quality of life and wellbeing. The latter is 
particularly relevant for their potential confounding influence on observed brain differences. 
For example depressive symptoms and mood disorders, which are highly comorbid in 
substance dependence 58, have also been associated with alterations of subcortical volumes 
(e.g., reduction in hippocampal volumes) 59. However, as not all sites in the current study 
collected information on depressive symptoms, or adopted common instruments in measuring 
them, their confounding influence on the current study findings cannot be ruled out. Moving 
forward, a standardized approach to recruiting and testing future samples (i.e., wherein all 
future substance dependence studies should collect information on duration, frequency, and 
quantity of substance use, and mood and anxiety symptoms, at the minimum) will be 
beneficial to allow for standardization and comparisons across datasets. This approach may in 
turn facilitate collaboration and crosstalk across studies, in clarifying substance-general and 
substance-specific brain correlates.  
 
To conclude, our comprehensive examination of subcortical morphology in the largest 
dependent user sample to date revealed significant alcohol and nicotine-specific effects on 
subcortical structures, in particular the hippocampus, thalamus, and putamen. By contrast, the 
effect of illicit substance dependence on brain volume was found to be minimal. Such 
findings might warrant a revised understanding of the structural correlates of addiction. It is 
possible that the brain-based effects of illicit substances may not be evident with 
morphological measurements, but may instead be confined to functional or connectivity-
related differences.  
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Table 1. Demographics of non-dependent controls and individuals with a substance dependence, across Models I - III (Mean (SD)) 
I Non-dependent 
controls 
N = 1535 
Dependent usersa 
 
N = 2270 
    
Sex (M/F %) 58.5/41.5 66.4/33.6*     
Age (Years) 27.5 (9.9) 32.7 (10.7)*     
ICV (106)b 1.44 (0.23) 1.49 (0.22)*     
II Non-dependent 
controls 
N = 1535 
AlcD 
 
N = 830 
NicD 
 
N = 565 
CocD 
 
N = 309 
MetD 
 
N = 171 
CbD 
 
N = 210 
Sex  (M/F %) 58.5/41.5 65.4/34.6* 57.5/42.5 78.3/21.7* 66.7/32.6* 69.5/30.5* 
Age (Years) 27.5 (9.9) 32.9 (11.3)* 31.1 (9.9)* 39.1 (8.1)* 31.1 (9.1)* 25.6 (9.3)* 
ICV (106) 1.44 (0.23) 1.53 (0.22)* 1.48 (0.22)* 1.41 (0.20) 1.55 (0.16)* 1.51 (0.19)* 
III Non-smoking 
controls 
N = 918 
Smoking 
controls 
N = 189 
NicD 
 
N = 565 
   
Sex (M/F %) 61.1/38.9 64.0/36.0 57.5/42.5    
Age (Years) 29.7 (9.6) 28.9 (9.4) 31.1 (9.9)*    
ICV (106) 1.41 (0.24) 1.52 (0.20)* 1.48 (0.22)*    
aSubstance dependence include AlcD = alcohol, NicD = nicotine, CocD = cocaine, MetD = meth, and CbD = cannabis dependence 
b ICV = intracranial volume, measured in mm3  
*p<.05. Each dependent group was compared against non-dependent controls (or non-smoking controls in Model III) with t-tests for Age and ICV and χ2 tests for Sex. 
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Table 2. Significant regions (as percentage of vertices, %) and average effect size (d) of differences in radial distance (RD) and Jacobian 
determinant (JD) common across splits 1 and 2, across Models I – III. 
Model Contrast Region Radial Distance (RD) Jacobian Determinant (JD) 
Percentage of 
total region (%) 
d* draw* p Percentage of 
total region (%) 
d* draw* p 
I Dependent 
users vs. 
non-
dependent 
controls 
Left Amygdala 0 - - - 0.66 -0.128 -0.141 0.009 
Hippocampus 3.24 -0.146 -0.162 0.005 28.70 -0.155 -0.169 0.005 
Thalamus 0.04 -0.127 -0.167 0.008 0.36 -0.152 -0.177 0.003 
Right Accumbens 10.65 -0.143 -0.174 0.005 0 - - - 
Amygdala 3.51 -0.172 -0.178 0.002 7.02 -0.149 -0.148 0.004 
Hippocampus 1.04 -0.146 -0.137 0.004 22.06 -0.164 -0.171 0.003 
Putamen 0 - - - 0.76 -0.150 -0.181 0.004 
Thalamus 1.76 -0.138 -0.154 0.005 2.32 -0.167 -0.163 0.002 
II Alcohol-
dependent 
users vs. 
non-
dependent 
controls 
Left Hippocampus 4.68 -0.168 -0.188 0.004 31.53 -0.170 -0.184 0.004 
Putamen 6.59 -0.155 -0.153 0.005 3.68 -0.143 -0.173 0.006 
Right Accumbens 0 - - - 1.94 -0.156 -0.188 0.004 
Amygdala 9.28 -0.163 -0.165 0.004 7.38 -0.158 -0.163 0.005 
Hippocampus 4.64 -0.160 -0.168 0.003 29.30 -0.172 -0.177 0.003 
Putamen 14.91 -0.155 -0.201 0.004 9.11 -0.156 -0.199 0.004 
Thalamus 8.63 -0.166 -0.167 0.004 16.39 -0.154 -0.175 0.004 
III Nicotine- Left Amygdala 0.95 0.137 0.112 0.006 0 - - - 
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dependent 
users vs. 
non-
smoking 
controls 
Hippocampus 5.84 0.150 0.167 0.005 45.24 0.166 0.173 0.003 
Putamen 6.75 0.155 0.181 0.004 6.59 0.158 0.183 0.003 
Thalamus 0 - - - 3.60 0.153 0.160 0.003 
Right Accumbens 3.55 0.161 0.182 0.003 9.14 0.141 0.166 0.006 
Amygdala 1.10 0.148 0.167 0.003 0 - - - 
Caudate 0.28 0.140 0.186 0.004 0 - - - 
Hippocampus 0.40 0.150 0.158 0.004 5.68 0.159 0.158 0.003 
Putamen 1.20 0.135 0.160 0.006 2.64 0.140 0.165 0.006 
Thalamus 9.11 0.157 0.160 0.003 7.43 0.165 0.159 0.002 
Smoking 
controls 
vs. non-
smoking 
controls 
 
Left Hippocampus 3.92 0.194 0.218 0.004 29.06 0.202 0.227 0.005 
Putamen 0.80 0.201 0.247 0.002 2.72 0.188 0.234 0.005 
Thalamus 0.03 0.189 0.240 0.004 2.32 0.182 0.219 0.006 
Right Accumbens 13.23 0.195 0.238 0.005 2.69 0.201 0.141 0.003 
Amygdala 0 - - - 0.365 0.207 0.193 0.002 
Hippocampus 0.68 0.205 0.193 0.002 9.67 0.210 0.215 0.004 
Pallidum 0 - - - 0 - - - 
Putamen 0 - - - 0.40 0.175 0.231 0.007 
Thalamus 4.52 0.193 0.210 0.004 5.875 0.214 0.222 0.002 
*Average effect size (d) computed over remaining significant regions after overlap of splits 1 and 2. Raw effect size (draw) represents effect size without correcting for 
covariates (age, sex, intracranial volume) 
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Figure Legend 
Fig. 1. Overview of the vertex-wise shape metrics employed. (A) 3D model of subcortical structures within the brain space. (B) The radial 
distance (RD) of a structure corresponds to the distance between each surface vertex and the structure’s medial skeleton. (C) The Jacobian 
determinant (JD) corresponds to the deformation necessary to match the subject-specific structure to a template. A higher JD reflects a larger 
‘surface area’ relative to the template. 
 
Fig. 2. Subcortical difference between individuals with substance dependence and non-dependent controls. Bottom and top view of (i) 
local surface thickness (radial distance, RD) and (ii) local area (natural logarithm of the Jacobian determinant, JD) differences across subcortical 
structures in the left (left) and right hemispheres (right), in individuals with substance dependence compared to non-dependent controls. All 
effects controlled for imaging site, sex, and age. Heat maps represent beta-values of the significant regions in each split half (SPLIT 1 and SPLIT 
2). Overlap in significance across both splits are colored in blue in the last column (OVERLAP). 
 
Fig. 3. Subcortical difference between individuals with alcohol dependence and non-dependent controls. Bottom and top view of (i) local 
surface thickness (radial distance, RD) and (ii) local area (natural logarithm of the Jacobian determinant, JD) differences across subcortical 
structures in the left (left) and right hemispheres (right), in individuals with an alcohol dependence (AlcD) compared to non-dependent controls. 
All effects controlled for imaging site, sex, and age. Heat maps represent beta-values of the significant regions in each split half (SPLIT 1 and 
SPLIT 2). Overlap in significance across both splits are colored in blue in the last column (OVERLAP). 
 
Fig. 4. Subcortical difference between individuals with nicotine dependence and non-smoking controls. Bottom and top view of (i) local 
surface thickness (radial distance, RD) and (ii) local area (natural logarithm of the Jacobian determinant, JD) differences across subcortical 
structures in the left (left) and right hemispheres (right), in individuals with a nicotine dependence (NicD) compared to non-smoking controls. 
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All effects controlled for imaging site, sex, and age. Heat maps represent beta-values of the significant regions in each split half (SPLIT 1 and 
SPLIT 2). Overlap in significance across both splits are colored in blue in the last column (OVERLAP). 
 
Fig. 5. Subcortical difference between smoking controls and non-smoking controls. Bottom and top view of (i) local surface thickness 
(radial distance, RD) and (ii) local area (natural logarithm of the Jacobian determinant, JD) differences across subcortical structures in the left 
(left) and right hemispheres (right), in smoking controls compared to non-smoking controls. All effects controlled for imaging site, sex, and age. 
Heat maps represent beta-values of the significant regions in each split half (SPLIT 1 and SPLIT 2). Overlap in significance across both splits 
are colored in blue in the last column (OVERLAP). 
 
